HIGHLIGHTS
- who: Xiaoyan Lu from the France Western University, London, ON, Canada have published the Article: Comparative efficacy of advanced treatments in biologic-nau00efve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis, in the Journal: (JOURNAL)
- what: Data on filgotinib were obtained from the study sponsor (Galapagos) ; two doses of filgotinib (200 mg and 100 mg) were considered in line with the registrational trial; however, only the results for filgotinib 200 mg, the licensed dose, are discussed further. This analysis demonstrated that most targeted therapies were superior to placebo and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.